Transactions
15
Insider / CLOROX CO /DE/
Breber Pierre R
Director at CLOROX CO /DE/
- Company
- CLOROX CO /DE/
- First filing on record
- October 2, 2025
- Latest trade on record
- October 1, 2026
- SEC filings
- EDGAR ↗
Breber Pierre R, Director at CLOROX CO /DE/, has disclosed 15 transactions in PCAR, CLX, LUV since October 2, 2025: 2 purchases (2 open-market buys) and 0 sales, worth about $896K at the reported prices. The latest was filed October 2, 2026, 1 day after the trade; 7 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
2
Sales
0
Avg. disclosure lag
17.2d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Breber Pierre R made 2 purchases worth $846K and no sales, plus 11 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Breber Pierre R has traded 1 stock on record; the largest by dollars is CLX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
5 of 9 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 12 | 7,566 | — |
| P | Open-market purchase | 2 | 9,000 | $846K |
| J | Other acquisition or disposal | 1 | 455 | $50K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 9 | 1 · $429K | 0 |
| 2025 | 6 | 1 · $417K | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| PCAR | Other J | October 1, 2026 | October 2, 2026 | 1d | 455 | $110 | $50K | derivative | Form 4 ↗ | |
| CLX | Other A | September 30, 2026 | October 2, 2026 | 2d | 417 | — | — | derivative | Form 4 ↗ | |
| CLX | Other A | August 28, 2026 | October 2, 2026 | 35d | 43 | — | — | latederivative | Form 4 ↗ | |
| CLX | Other A | June 30, 2026 | July 2, 2026 | 2d | 354 | — | — | derivative | Form 4 ↗ | |
| CLX | Other A | May 8, 2026 | July 2, 2026 | 55d | 42 | — | — | latederivative | Form 4 ↗ | |
| LUV | Other A | May 7, 2026 | May 11, 2026 | 4d | 4,108 | — | — | Form 4 ↗ | ||
| CLX | Buy P | May 5, 2026 | May 5, 2026 | 0d | 5,000 | $86 | $429K | indirect | Form 4 ↗ | |
| CLX | Other A | March 31, 2026 | April 2, 2026 | 2d | 326 | — | — | derivative | Form 4 ↗ | |
| CLX | Other A | February 13, 2026 | April 2, 2026 | 48d | 27 | — | — | latederivative | Form 4 ↗ | |
| CLX | Other A | December 31, 2025 | January 5, 2026 | 5d | 335 | — | — | latederivative | Form 4 ↗ | |
| CLX | Other A | December 31, 2025 | January 5, 2026 | 5d | 1,638 | — | — | latederivative | Form 4 ↗ | |
| CLX | Other A | November 6, 2025 | January 5, 2026 | 60d | 9 | — | — | latederivative | Form 4 ↗ | |
| CLX | Buy P | November 21, 2025 | November 24, 2025 | 3d | 4,000 | $104 | $417K | indirect | Form 4 ↗ | |
| CLX | Other A | September 30, 2025 | October 2, 2025 | 2d | 264 | — | — | derivative | Form 4 ↗ | |
| CLX | Other A | August 29, 2025 | October 2, 2025 | 34d | 5 | — | — | latederivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 2, 2026 | Form 4 | 0001225208-26-008108 | 2 | published | EDGAR ↗ |
| October 2, 2026 | Form 4 | 0001225208-26-008132 | 1 | published | EDGAR ↗ |
| July 2, 2026 | Form 4 | 0001225208-26-006376 | 2 | published | EDGAR ↗ |
| May 11, 2026 | Form 4 | 0000092380-26-000066 | 1 | published | EDGAR ↗ |
| May 5, 2026 | Form 4 | 0001225208-26-004962 | 1 | published | EDGAR ↗ |
| April 2, 2026 | Form 4 | 0001225208-26-004191 | 2 | published | EDGAR ↗ |
| January 5, 2026 | Form 4 | 0001225208-26-000171 | 3 | published | EDGAR ↗ |
| November 24, 2025 | Form 4 | 0001225208-25-009410 | 1 | published | EDGAR ↗ |
| October 2, 2025 | Form 4 | 0001225208-25-008288 | 2 | published | EDGAR ↗ |
Other insiders at CLOROX CO /DE/
- WEINER RUSSELL J Chief Executive Officer 21 rows
- WILLIAMS CHRISTOPHER J Director 21 rows
- Liberty Jason T President & CEO 19 rows
- Plaines Stephanie Director 12 rows
- Hyder Chris T EVP-Group Pres -Hlth & Hyg 11 rows
- Shattock Matthew J Director 11 rows
- Atherton Lisa M President and CEO 9 rows
- Bellet Luc EVP - Chief Financial Officer 9 rows
- Hilt Angela C EVP - Chief Legal Officer 9 rows
- Marriner Kirsten EVP - Chief Admin Officer 9 rows
Everyone on file, with contracts and lobbying under the company's name: CLOROX CO /DE/.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 9 | 15 | October 2, 2025 | October 2, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.